US 12,291,526 B2
Deuterated derivatives of lanifibranor
Christian Montalbetti, Fontaine-les-Dijon (FR); and Benaissa Boubia, Saint Apollinaire (FR)
Assigned to INVENTIVA, Daix (FR)
Appl. No. 17/261,938
Filed by INVENTIVA, Daix (FR)
PCT Filed Jul. 26, 2019, PCT No. PCT/FR2019/051860
§ 371(c)(1), (2) Date Jan. 21, 2021,
PCT Pub. No. WO2020/021215, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 18 57021 (FR), filed on Jul. 27, 2018.
Prior Publication US 2021/0300913 A1, Sep. 30, 2021
Int. Cl. C07D 417/12 (2006.01)
CPC C07D 417/12 (2013.01) [C07B 2200/05 (2013.01)] 6 Claims
 
1. A deuterated derivative of lanifibranor, which is 4-[1-[(2-deuterio-1,3-benzothiazol-6-yl)sufonyl]-5-chloro-1H-indol-2-yl]butanoic acid.